Imagine a future where we can harness the power of our own immune cells to fight cancer that has spread to the brain. That future is closer than you think. A groundbreaking study has revealed that CAR T-cell therapy, a revolutionary immunotherapy approach, shows promising early signs of safety and effectiveness in patients with recurrent brain or leptomeningeal metastases from HER2-positive breast cancer. But here's where it gets even more fascinating: this treatment, when administered directly into the brain's ventricles, has demonstrated the potential to stabilize the disease, offering a glimmer of hope where traditional therapies often fall short.
In a phase 1 trial (NCT03696030) presented at the 2025 Society of Neuro-Oncology Annual Meeting, researchers explored the use of HER2-directed CAR T-cell therapy, both with and without lymphodepletion (LD). The results were eye-opening. Patients experienced stable disease (SD) as the best response, with SD rates of 44% in those receiving CAR T-cell therapy alone and 64% in those who also underwent LD. However, the addition of LD came with a trade-off: while it showed evidence of on-target activity, it also increased toxicity, as highlighted by two instances of dose-limiting toxicities (grade 3 headaches) that prevented further treatment.
And this is the part most people miss: the therapy’s side effects were generally manageable, with the most common being grade 1/2 headaches, nausea, fever, fatigue, and muscle pain, typically lasting only 24 to 48 hours. Two patients experienced possible grade 1/2 immune effector cell–associated neurotoxicity syndrome, manifesting as confusion and lethargy, but these cases were rare and closely monitored.
Lead study author Jana Portnow, MD, a professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Brain Tumor Program at City of Hope, emphasized the therapy’s initial safety profile. However, she also noted that LD, while enhancing CAR T-cell persistence in the cerebrospinal fluid (CSF), did not significantly improve the durability of SD. This raises a thought-provoking question: Is the increased toxicity of LD worth the potential benefits, or are there alternative strategies to enhance CAR T-cell efficacy without compromising safety?
The study’s design was meticulous. Patients aged 18 and older with histologically confirmed HER2-positive breast cancer and recurrent brain or leptomeningeal metastases were enrolled. The HER2-directed CAR T-cell therapy was evaluated at three escalating dose levels, with LD consisting of cyclophosphamide and fludarabine. The primary endpoint focused on safety, while secondary endpoints included CAR T-cell persistence, immune system activation, cytokine changes, and clinical benefit in the central nervous system (CNS).
Correlative analyses provided additional insights. Escalating doses and the addition of LD led to modest increases in CAR T-cell persistence in the CSF. A compelling case study of a 54-year-old woman revealed that after LD and CAR T-cell therapy, malignant cells in her CSF cytology disappeared entirely by the fifth dose. Furthermore, the therapy induced a shift in cytokine levels, initially increasing pro-inflammatory cytokines, which later gave way to anti-inflammatory cytokines, suggesting a dynamic immune response.
This study not only underscores the potential of CAR T-cell therapy in treating challenging brain metastases but also opens the door to further exploration. What do you think? Is this the beginning of a new era in cancer treatment, or are we still far from fully unlocking the potential of CAR T-cell therapy? Share your thoughts in the comments below and let’s spark a conversation about the future of oncology.
